Andrew McKeon, M.B., B.Ch., M.D.

Closed for Enrollment

• A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Basket Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients with Anti-N-Methyl-D-Aspartic Acid Receptor (NMDAR) or Anti-Leucine-Rich Glioma-Inactivated 1 (LGI1) Encephalitis (CIELO) Rochester, Minn., Scottsdale/Phoenix, Ariz.

  The purpose of this study is to assess the effectiveness, safety, pharmacokinetics, and pharmacodynamics of satralizumab in participants with anti--N‑methyl-D‑aspartic acid receptor (NMDAR) and anti--leucine‑rich glioma‑inactivated 1 (LGI1) encephalitis. 

   

• Immune Phenotyping of Patients with Inflammatory Central Nervous System Disorders Rochester, Minn.

  This research is being done to see if blood and spinal fluid can be used for future diagnostic tests to help diagnose, treat and give prognosis to patients with inflammatory CNS diseases.

• Randomized Placebo Controlled Trial of IVIg in Glycine Receptor Antibody Positive Stiff-Person Syndrome (SPS) Spectrum Disorders Rochester, Minn.

  The purpose of this study is to assess in a blinded, randomized controlled fashion, whether 9 weeks of immunoglobulin therapy (IVIG) can reduce stiffness and spasms in subjects with Stiff-Person Syndrome (SPS).